We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -256.00 | -2.14% | 11,708.00 | 11,710.00 | 11,716.00 | 11,908.00 | 11,678.00 | 11,844.00 | 2,989,208 | 16:35:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 54.07B | 7.04B | 4.5371 | 25.82 | 185.51B |
From Feb 2020 to Feb 2025
TIDMAZN
RNS Number : 8898G
AstraZeneca PLC
01 June 2017
1 June 2017 15:00 BST
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 1 JUNE 2017
Hot Features
Premium
Name of applicant: ASTRAZENECA PLC
--------------------------------------------------- -----------------------------------------------------------------
Name of scheme: ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE
OPTION PLAN; ASTRAZENECA
ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED
SHARE OPTION SCHEME
--------------------------------------------------- -----------------------------------------------------------------
Period of return: From: 1 DECEMBER 2016 To: 31 MAY 2017
------------------------- ------------------------ ------------------------- ----------- -------------------------
Balance of unallotted securities under scheme(s)
from previous return: 3,587,335
--------------------------------------------------- -----------------------------------------------------------------
Plus: The amount by which the block scheme(s) has
been increased since the date of the last
return (if any increase has been applied for): 0
--------------------------------------------------- -----------------------------------------------------------------
Less: Number of securities issued/allotted under
scheme(s) during period (see LR3.5.7G): 695,679
--------------------------------------------------- -----------------------------------------------------------------
Equals: Balance under scheme(s) not yet
issued/allotted at end of period: 2,891,656
--------------------------------------------------- -----------------------------------------------------------------
Name of contact: CAMILLA WISEMAN
------------------------------ ----------------
Telephone number of contact: 020 3749 5000
------------------------------ ----------------
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
Media Relations Esra Erkal-Paler UK/Global +44 203 749 5638 Karen Birmingham UK/Global +44 203 749 5634 Rob Skelding UK/Global +44 203 749 5821 Jacob Lund Sweden +46 8 553 260 20 Michele Meixell US +1 302 885 2677 Investor Relations Thomas Kudsk Larsen +44 203 749 5712 Craig Marks Finance, Fixed Income, M&A +44 7881 615 764 Henry Wheeler Oncology +44 203 749 5797 Mitchell Chan Oncology +1 240 477 3771 Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970 Nick Stone Respiratory +44 203 749 5716 Christer Gruvris Autoimmunity, Neuroscience & Infection +44 203 749 5711 US toll free +1 866 381 7277
Adrian Kemp
Company Secretary, AstraZeneca PLC
This information is provided by RNS
The company news service from the London Stock Exchange
END
BLRSSEFEFFWSEEM
(END) Dow Jones Newswires
June 01, 2017 10:00 ET (14:00 GMT)
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
